VANCOUVER, British Columbia, June 01, 2021 (GLOBE NEWSWIRE) – Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021, it will change its name to KetamineOne Capital Limited (“Ketamine A“or the”Company“) of Myconic Capital Corp. and do business under the brand name” Ketamine One “(the”Name change“). At the same time, the Company will change to a sole purpose company of an investment issuer. Ketamine One will continue to trade under the ticker symbol “MEDI” on the NEO Exchange (“NEO”). The Company has also significantly expanded its management team with the appointment of a Medical Director, a Director of Research and a President of Clinical Operations.
The Ketamine One Board of Directors has appointed Dr Mark Kimmins as the Company’s Medical Director. Dr Kimmins is a physician and surgeon, Fellow of the American College of Surgeons, Fellow of the Royal College of Surgeons of Canada, and Fellow of the American Society of Colon and Rectal Surgeons. He has extensive experience in academic medicine, subspecialty community medicine, cannabis medicine, and health-related affairs, which are areas of expertise that will be applied to help lead as a leader of the company.
Najla Guthrie has been appointed by the company’s board of directors as the director of research. Ms. Guthrie joins Ketamine One in the previously announced acquisition of KGK Science Inc. from Auxly Cannabis Group Inc., where she has served as President and CEO since 1997. Over 23 years, Najla has developed the London-based company. to become a leading contract research organization in North America that primarily provides high quality clinical research trials with a focus on the emerging nutraceutical, cannabis and psychedelic industries.
Additionally, Keith White has been hired by the company as President of Clinical Operations. Mr. White joins Ketamine One in the previously announced acquisition of 14 medical cannabis clinics, in the same role he held with Aleafia Health to ensure the continuity and continued growth of clinical assets. During his tenure, he led patient growth initiatives that resulted in an 84% annual increase in medical cannabis sales, while rapidly implementing scalable technology solutions to allow patient care to continue virtually. during the COVID-19 pandemic. Keith is a dynamic executive with over 20 years of senior leadership experience in growth-oriented private healthcare companies.
“We are delighted to reveal the company’s new branding in Ketamine One, which more accurately reflects our vision to quickly become a leader in providing breakthrough treatments for mental wellness,” said Adam Deffett, vice-president. President of Capital Markets for Ketamine One. “The new corporate identity is another step in creating a network of critical infrastructure needed to safely advance innovative mental wellness treatments and technologies, and today’s executive appointments. ‘hui provide the experience necessary to execute this strategy. Having recently completed two significant acquisitions and increased its operational and strategic strength with additional leadership, Ketamine One is poised to accelerate its plan to consolidate and add value to medical clinics and research facilities in North America, ”added Mr. Deffett.
In accordance with the name change, the Company launched its new website at www.ketamine.one. The new website showcases the strength and clarity of the new Ketamine One brand, with content that includes, but is not limited to, the company, market potential, mental health, investor materials and the news. In addition, contact details for investors and other interested parties appearing on the website as well as in this press release have been updated to reflect the name change. Employee email addresses have also been updated, while Ketamine One’s new social media profiles have been secure and will be launched in due course.
As part of its transformation into a single purpose business, Ketamine One will reconfigure its operating assets, investments and other resources to focus on achieving its vision of becoming a North American leader in mental health. . A material change report related to the name change will be filed by the company within 10 days of the effective date of the name change.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) (NEO: MEDI) is a single-purpose company focused on becoming a North American leader in mental health. In 2021, the Company acquired a network of 14 national medical cannabis clinics as well as KGK Science Inc., a leading contract research organization in North America that delivers high-quality clinical research trials focused on industries. nutraceutical, cannabis and emerging psychedelic. .
On behalf of:
Robert Meister, CEO and Director
For more information, please contact:
Notice regarding forward-looking information:
This press release contains forward-looking statements, including, but not limited to, statements regarding the business, assets or investments of the Company, as well as other statements which are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will be achieved. By their nature, forward-looking statements involve many assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. which may cause the performance and results of future periods to differ materially from any estimate or projection of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and the financial markets in particular, the interest of investors in the activities and future prospects of the Company.
The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required. by applicable securities law. Further, the Company assumes no obligation to comment on any expectations or statements made by third parties with respect to the matters discussed above.